CBAY
- CymaBay Therapeutics, Inc.
()
Overview
Company Summary
CymaBay Therapeutics, Inc. (CBAY) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for patients with liver and metabolic diseases. The company primarily works on developing small molecule drugs that target nuclear receptors, which are critical proteins involved in regulating various biological processes.
CymaBay Therapeutics' research and development efforts primarily focus on two main therapeutic areas: liver diseases and metabolic disorders. In the liver diseases area, the company is dedicated to finding treatments for nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and rare liver diseases. These conditions have limited treatment options, and CymaBay aims to address the unmet medical needs of patients with these conditions.
The company's metabolic disorders programs revolve around developing therapies for patients with dyslipidemia and familial hypercholesterolemia (FH). CymaBay Therapeutics aims to create treatments that can effectively lower cholesterol and triglyceride levels in these patients, thereby reducing the risk of cardiovascular diseases associated with high cholesterol.
To develop these therapies, CymaBay Therapeutics utilizes their expertise in nuclear receptor pharmacology and biology. The company's drug candidates target specific nuclear receptors that are involved in regulating cholesterol synthesis, lipid metabolism, and inflammation in the liver. By modulating these receptors, CymaBay endeavors to develop potentially effective and safe treatments for patients with liver and metabolic diseases.
In summary, CymaBay Therapeutics, Inc. is a biopharmaceutical company focused on the development of innovative therapies for liver diseases like NASH and PBC, as well as metabolic disorders such as dyslipidemia and FH. Their research and development efforts primarily revolve around small molecule drugs that target nuclear receptors, aiming to address unmet medical needs in these areas.